Trichophyton indotineae is described in the report as an emerging dermatophyte that is frequently resistant to terbinafine. Analysis of identification data produced by the Mass Spectrometry Identification (MIND) global network revealed a threefold increase in T. indotineae identifications during 2022–2025. The observed rise in identifications across the network indicates a meaningful increase in detection and suggests wider geographic spread of this pathogen over the study interval.
The abstract emphasizes the temporal trend (2022–2025) and reports the quantitative result as a threefold increase; however, the abstract does not supply additional breakdowns such as case counts by year, regional distribution, or the absolute number of identifications. Those specifics were not reported in the abstract provided.
The authors used data produced by the global Mass Spectrometry Identification network to track T. indotineae. The report highlights that this application of mass spectrometry identification is effective for monitoring the global spread of the pathogen. The manuscript frames the MIND network as a public health surveillance tool that can detect changes in identification frequency over time and across participating sites.
The abstract does not include detailed methods for the mass spectrometry workflow, criteria for species identification, participating laboratory list, or the exact data aggregation and analysis procedures used by the MIND network. Those methodological details were not reported in the abstract.
T. indotineae is noted for frequent resistance to terbinafine, which carries clinical significance because terbinafine is a frontline antifungal for dermatophyte infections. The emergence and apparent global spread of a terbinafine-resistant dermatophyte have implications for clinical management, antifungal stewardship, and public health surveillance. The authors list keywords including antifungal drug resistance, antimicrobial resistance, dermatophyte infection, fungal skin diseases, mass spectrometry, and public health surveillance, indicating the intersection of clinical microbiology and epidemiology in the report.
Beyond stating the association with terbinafine resistance, the abstract does not report susceptibility percentages, alternative treatment options, outcomes, or patient-level clinical data. Those data were not reported in the abstract.
The abstract summarizes the principal finding (threefold increase in identifications) and asserts that mass spectrometry identification via the MIND network is an effective monitoring approach. However, the abstract lacks several details that would be needed to fully interpret the finding and its generalizability:
Because these items are not presented in the abstract text available here, readers should consult the full text for methodological details, numerical data, and comprehensive interpretation.
The report appears in Emerging Infectious Diseases (2026 Sep;32[9]:1487–1491) and is listed as a free article. The PubMed entry records the PMID 42661283 and DOI 10.3201/eid3209.260463. The author group includes Arnaud Jabet and collaborators from the MIND Study Group and additional coauthors. Keywords provided in the PubMed record include France; antifungal drug resistance; antimicrobial resistance; dermatophyte infection; fungal skin diseases; fungi; mass spectrometry; public health surveillance; sexually transmitted infections; and zoonoses.
Readers seeking full methodological information, detailed results (including counts, locations, and susceptibility data), and discussion of clinical management implications should refer to the full article, as the abstract alone does not provide those details.